IFITM10

Across TCGA pan-cancer cohorts, IFITM10 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of IFITM10’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where IFITM10 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types IFITM10 is over-expressed in tumor, although a few such as PRAD show the opposite, repressed pattern.

THCA, KIRC, and KIRP are the cancer types where IFITM10 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IFITM10 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	+1.210	<.001	11	view →
KIRC	Male	II,III,IV	+0.838	<.001	10	view →
KIRP	Male	III,IV	+1.635	<.001	9	view →
STAD	Male	II,III,IV	+1.598	<.001	9	view →
KICH	Female	II,III,IV	+1.817	<.001	7	view →
BRCA	All	III,IV	+0.623	.028	3	view →
PRAD	All	All	−0.568	<.001	2	view →
LUAD	Female	All	+0.396	.019	2	view →
LIHC	All	II,III,IV	+0.541	.038	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

IFITM10–THCA

Open the THCA breakdown →